We are live on ! Find out more

Incannex Healthcare

IXHL

Market cap $42.8M

3.58 USD

-0.22

5.79%

At close Updated Sep 17, 1:46 PM EDT

1 day

-5.79%

5 days

10.15%

1 month

7.83%

3 months

-3.24%

6 months

8.16%

Year to date

-69.4%

1 year

-77.4%

5 years

-99.8%

10 years

-99.8%

About: Incannex Healthcare Inc is a clinical stage pharmaceutical company developing medical cannabis products for the treatment of Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI)/Concussion, Rheumatoid Arthritis, Inflammatory Bowel Disease, and Inflammatory Lung Conditions. The company has an Australian license to import, export, and distribute medicinal cannabis products and has launched a line of cannabinoid products. The Company operates and manages its business as one reportable and operating segment, which is the Research and Development of the use of psychedelic medicine and therapies.

Employees: 12

Healthcare Drug Manufacturers - Specialty & Generic

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Patient dosing commenced in the DReAMzz Phase 2 dose-optimization study of IHL-42X in obstructive sleep apnea U.S. composition and methods of treatment patent granted covering IHL-42X with baseline expiry in 2040 Approximately $70 million in cash and no debt, including more than A$11.2 million in non-dilutive capital received during 2026 NEW YORK and MELBOURNE, Australia, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today provides a corporate update reporting the dosing of the first patient in its DReAMzz Phase 2 study of IHL-42X in obstructive sleep apnea, the grant of a U.S. composition patent covering IHL-42X, and a cash position of approximately $70 million with no debt.

Incannex Healthcare Provides Corporate Update on Clinical Progress, Intellectual Property and Capital Position

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation First patient dosing represents another major clinical milestone for IHL-42X, building on positive Phase 2 RePOSA results demonstrating reductions in AHI of up to 83% and FDA Fast Track designation

Incannex Announces First Patient Dosed in DReAMzz Phase 2 Study of IHL-42X

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative therapies for high-impact indications, is pleased to announce that participant screening has commenced in the Company's DReAMzz Phase 2 dose confirmation study evaluating IHL-42X for the treatment of obstructive sleep apnea (“OSA”). IHL-42X has previously been granted Fast Track designation by the U.S. Food and Drug Administration (“FDA”), underscoring its potential to address the significant unmet medical need in OSA and providing opportunities for more frequent interactions with the FDA throughout the development process, supporting a potentially expedited pathway towards regulatory review.

Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

MELBOURNE, Australia and NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company developing innovative combination therapies for high-impact indications, today announced that the United States Patent and Trademark Office (USPTO) has granted a key patent titled “Compositions and Methods of Treatment for Obstructive Sleep Apnea.” The granted patent includes claims directed to the proprietary IHL-42X composition and its associated therapeutic methods for the treatment of Obstructive Sleep Apnea (OSA).

Incannex Secures U.S. Patent Grant for IHL-42X in Obstructive Sleep Apnea

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026 In addition to the A$6.0 million refund received, the Company expects a further approximately A$5.1 million in R&D Tax Incentive proceeds later this year, bringing total expected non-dilutive funding under the program to more than A$11.1 million received in 2026

Incannex Receives A$6.0 Million R&D Tax Incentive Refund for FY25, Further Strengthening Balance Sheet and Financial Flexibility

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

MELBOURNE, Australia and NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing innovative combination therapies and next-generation medicines for high-impact indications, is pleased to announce that Alliance Global Partners (“AGP”) has initiated equity research coverage of the Company.

Incannex Announces Initiation of Research Coverage by Alliance Global Partners

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activated Major operational milestone achieved as Incannex advances late-stage development of IHL-42X, with all clinical sites identified and trial infrastructure activated

Incannex Healthcare Officially Commences DReAMzz Clinical Study for IHL-42X in Obstructive Sleep Apnea

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

MELBOURNE, Australia and NEW YORK, May 12, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company advancing innovative combination therapies for high-impact indications, today announced it has been named the winner of the “Best New Technology Solution for Drug Development” award in the 10th annual MedTech Breakthrough Awards program. The award recognizes Incannex's lead drug candidate, IHL-42X, an oral fixed-dose combination therapy in development for the treatment of obstructive sleep apnea (OSA), and reinforces the Company's growing position at the forefront of next-generation therapeutic innovation.

Incannex Healthcare Wins MedTech Breakthrough Award for IHL-42X, Underscoring Leadership in Next-Generation Drug Development

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide Landmark 10th Annual Awards Program Recognizes the Most Innovative Digital Health and Medical Technology Solutions Worldwide

Incannex Healthcare Recognized for Innovative Drug Development Solutions by MedTech Breakthrough

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

MELBOURNE, Australia and NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing innovative combination therapies, today supports the White House Executive Order signed by President Donald J. Trump on April 18, 2026, titled, “Accelerating Medical Treatments for Serious Mental Illness.

Incannex Healthcare PSX-001 Program Aligns with White House Executive Order Accelerating Access to Psychedelic Treatments for Serious Mental Illness

See News Rankings

Price charts implemented using Lightweight Charts™